Business
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"image","alt":"Eupraxia Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Eupraxia Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yASLZxJ58EV1_UWBsu0OKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b","width":300,"height":123}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. ","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis.","length":212,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":631,"olType":false},{"type":"text","content":"VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE").","length":560,"tagName":"p"},{"type":"text","content":""These tissue health data provide compelling evidence supporting our belief that EP-104GI is addressing the underlying pathology of EoE at the tissue level, as well as managing symptoms," said Dr. James A. Hel...